Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
MRK had a Rule 144 notice filed for a planned sale of 15,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 1,827,991.50. The filing lists 2,482,022,536 shares of common stock outstanding.
The shares to be sold were acquired mainly through restricted stock vesting under a registered plan on multiple dates between May 2022 and January 2025, plus a small private acquisition from the issuer. The signer represents they are not aware of undisclosed material adverse information about the issuer.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III reported exercising stock options and selling shares of common stock. On 02/04/2026, he exercised an option for 4,000 shares of Merck common stock at an exercise price of $62.07 per share.
On the same date, Smart reported selling 4,000 Merck common shares at $119.675 per share, followed by an additional sale of 2,400 shares at the same price. After these transactions, he directly owned 8,204.816 shares of Merck common stock. The option originally vested in three equal annual installments beginning in 2018.
Merck & Co., Inc. President, U.S. Market, Johannes Jacobus Oosthuizen reported selling 15,000 shares of Merck common stock on February 6, 2026 at a weighted average price of $121.8661 per share. The sale occurred in multiple trades between $121.8200 and $121.9500. After this transaction, he directly beneficially owned 21,197.389 Merck shares.
Merck & Co., Inc. executive vice president and CFO Caroline Litchfield reported an option exercise and share sale. On February 4, 2026, she exercised 41,997 stock options at an exercise price of $53.06 per share, receiving the same number of common shares.
On the same date, she sold 41,997 Merck common shares at a weighted average price of $119.6112 per share, in multiple trades between $119.5400 and $119.7800. After these transactions, she directly owned 90,192.194 Merck common shares.
Merck & Co., Inc. executive Dean Y. Li reported an option exercise and share sale. On 02/04/2026 he exercised a stock option for 15,087 shares of common stock at an exercise price of $56.04 per share, increasing his direct holdings to 117,357.05 shares.
That same day, he sold 15,087 shares of Merck common stock at a weighted average price of $118.7661 per share, in multiple trades between $118.7200 and $118.8300. After the sale, he directly owned 102,270.05 Merck shares.
Merck & Co., Inc. executive stock sale: Chief Marketing Officer Chirfi Guindo sold 20,000 shares of Merck common stock on February 5, 2026 in an open-market transaction. The weighted average sale price was $121.8838 per share, with individual trades ranging from $121.84 to $121.97.
After this sale, Guindo still directly owns 80,615.127 Merck shares, so he remains a significant internal shareholder. The filing notes that detailed trade prices within the reported range are available on request from Merck, its security holders, or the SEC staff.
Merck & Co., Inc. executive Richard R. DeLuca, Jr. reported a sale of company stock. On 02/06/2026, he sold 37,685 shares of Merck common stock at a weighted average price of $120.9241 per share, in multiple trades between $120.7350 and $121.3054.
After this transaction, DeLuca directly beneficially owned 160,173.834 Merck shares. The filing lists him as Executive Vice President and President, Merck Animal Health, and shows no derivative securities activity for this date.
Merck & Co., Inc. Chairman, CEO and President Robert M. Davis reported two open-market sales of Merck common stock on February 4, 2026. He sold 14,972 shares at a weighted average price of $117.3796 per share and 32,462 shares at a weighted average price of $118.3513 per share, with both transactions coded as sales. After these trades, he directly beneficially owned 443,601.757 shares of Merck common stock.
A holder of Common Stock of the issuer has filed a notice of proposed sale of 20,000 shares under Rule 144. The shares have an indicated aggregate market value of $2,437,676.00 and are planned to be sold on the NYSE around 02/05/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
The shares to be sold were acquired from the issuer as restricted stock vesting under a registered plan in several transactions during 2024, including lots of 19,489, 132, 127, and 125 shares. The notice states there are 2,482,022,536 shares of this class outstanding.
An MRK shareholder has filed a notice of intent to sell 6,400 shares of common stock, with an aggregate market value of $765,920, through Morgan Stanley Smith Barney LLC on 02/04/2026 on the NYSE.
The shares to be sold were acquired mainly through restricted stock vesting under a registered plan on several dates in 2024 and through the exercise of 4,000 options on 02/04/2026. The issuer had 2,482,022,536 shares outstanding at the time referenced.